Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021

Laura D Zambrano,Margaret M Newhams,Samantha M Olson,Natasha B Halasa,Ashley M Price,Julie A Boom,Leila C Sahni,Satoshi Kamidani,Keiko M Tarquinio,Aline B Maddux,Sabrina M Heidemann,Samina S Bhumbra,Katherine E Bline,Ryan A Nofziger,Charlotte V Hobbs,Tamara T Bradford,Natalie Z Cvijanovich,Katherine Irby,Elizabeth H Mack,Melissa L Cullimore,Pia S Pannaraj,Michele Kong,Tracie C Walker,Shira J Gertz,Kelly N Michelson,Melissa A Cameron,Kathleen Chiotos,Mia Maamari,Jennifer E Schuster,Amber O Orzel,Manish M Patel,Angela P Campbell,Adrienne G Randolph,Overcoming COVID-19 Investigators,Meghan Murdock,Mary Glas Gaspers,Katri V Typpo,Connor P Kelley,Ronald C Sanders,Masson Yates,Chelsea Smith,Katheryn Crane,Geraldina Lionetti,Juliana Murcia-Montoya,Matt S Zinter,Denise Villarreal-Chico,Adam L Skura,Harvey Peralta,Justin M Lockwood,Emily Port,Imogene A Carson,Brandon M Chatani,Laila Hussaini,Nadine Baida,Bria M Coates,Courtney M Rowan,Mary Stumpf,Marla S Johnston,Benjamin J Boutselis,Suden Kucukak,Sabrina R Chen,Edie Weller,Laura Berbert,Jie He,Heidi R Flori,Janet R Hume,Ellen R Bruno,Lexie A Goertzen,Emily R Levy,Supriya Behl,Noelle M Drapeau,Lora Martin,Lacy Malloch,Cameron Sanders,Kayla Patterson,Anita Dhanrajani,Shannon M Hill,Abigail Kietzman,Valerie H Rinehart,Lauren A Hoody,Stephanie P Schwartz,Angelo G Navas,Paris C Bennett,Nicole A Twinem,Merry L Tomcany,Mary Allen Staat,Chelsea C Rohlfs,Amber Wolfe,Rebecca L Douglas,Kathlyn Phengchomphet,Megan M Bickford,Lauren E Wakefield,Laura Smallcomb,Laura S Stewart,Meena Golchha,Jennifer N Oates,Cindy Bowens

DOI: https://doi.org/10.15585/mmwr.mm7102e1

2022-01-14

Abstract:Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),§ and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6). Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated. The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design¶ among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance. Patients with MIS-C (case-patients) and two groups of hospitalized controls matched to case-patients were evaluated: test-negative controls had at least one COVID-19-like symptom and negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen-based assay results, and syndrome-negative controls were hospitalized patients without COVID-19-like illness. Among 102 MIS-C case-patients and 181 hospitalized controls, estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%-97%). All 38 MIS-C patients requiring life support were unvaccinated. Receipt of 2 doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18 years, highlighting the importance of vaccination among all eligible children.